Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen BioscienceFRA:OCD1 67 Median PS Value is €6.25 as of Jul. 29, 2026, which is 100% below its 10-year median of 0.72. GuruFocus rates FRA:OCD1 with a GF Score™ of 67/100 and a GF Value™ of €3.98 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 277 Biotechnology companies, Niagen Bioscience ranks better than 69.68% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Niagen Bioscience's Median PS Value or its related term are showing as below:
FRA:OCD1'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18 Med: 0.72 Max: 1.83
Current: 0.41
During the past 13 years, the highest Price to Median PS Value of Niagen Bioscience was 1.83. The lowest was 0.18. And the median was 0.72.
FRA:OCD1's Price-to-Median-PS-Value is ranked better than 69.68% of 277
companies
in the Biotechnology industry
Industry Median: 0.62
vs FRA:OCD1: 0.41
Niagen Bioscience (FRA:OCD1) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Niagen Bioscience's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.58
/
6.25
=
0.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience Median PS Value Related Terms
Niagen Bioscience Median PS Value Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OCD1 vs LCTX, IFRX, VRXA: Median PS Value Comparison
For the Biotechnology subindustry, Niagen Bioscience's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.7783.
Niagen Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.308.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (FRA:OCD1) has a Median PS Value of €6.25 as of Jul. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Niagen Bioscience and its competitors. This is 768% above median its historical median of 0.72. Over the past decade, Niagen Bioscience's Median PS Value has ranged from 0.18 to 1.83. According to the industry distribution chart, Niagen Bioscience ranks #84 out of 277 companies in the Biotechnology industry, placing it in the top 30.3%.
Is Niagen Bioscience's Median PS Value too high?
Niagen Bioscience's current Median PS Value of €6.25 is 768% above median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.83. Based on the distribution chart, Niagen Bioscience ranks #84 out of 277 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Median PS Value compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #84 out of 277 companies for Median PS Value. This puts Niagen Bioscience in the upper half of its industry. The industry median Median PS Value is 0.62. Historically, Niagen Bioscience's own Median PS Value has ranged from 0.18 to 1.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Median PS Value is €6.25, which is 768% above median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current Median PS Value is €6.25, which is 768% above median its 10-year median of 0.72. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Median PS Value is €6.25 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for FRA:OCD1:
Median PS Value: €6.25 (768% above median its 10-year median of 0.72)
GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for FRA:OCD1
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
